This guidance document proposes an integrated approach on testing and assessment for skin corrosion and irritation, in view of replacing the "testing and evaluation strategy" provided in the supplement to OECD TG404 (to be updated), provides information on key performance characteristics of each information source comprising the IATA, and guidance on how to integrate information for decision making for classification and labeling.
This webpage gives information about a series of Frequently Asked Questions (FAQ) raised by testing laboratories about implementation of GLP, along with responses prepared by the Working Group on GLP. This current version concerns questions about Quality Assurance, and the FAQ document will be amended, from time-to-time, to include new questions and answers.
This section addresses questions and answers regarding the OECD Test Guidelines Programme (TGP).
Presentation by Endpoints: Section 2 - Effects on Biotic Systems
On 26 July 2013, the OECD Council adopted three new, six updated and one corrected OECD Test Guidelines for the testing of chemicals, as well as a new Introduction to the Section 5, Part A on Pesticides Residue Chemistry.
This biocide document provides guidance on the conduct of laboratory and field tests aimed to assess the efficacy of anti-ants baits for indoor use. A bait contains one or more insecticidal active ingredients combined with food for garden ants.
Seven new publications are available in the OECD Series on Testing and Assessment, No. 151 and No.186 to No.191. Most of them accompany existing OECD Test Guidelines, or provide guidance for specific areas of chemical safety testing (e.g. microbicide or biocide efficacy testing).
OECD Work Related to Endocrine Disrupters
This document describes four quantitative methods for efficacy evaluation: bactericidal, mycobactericidal, fungicidal and virucidal. Regulatory authorities have relied upon efficacy data generated using these methods to authorise the placing of biocidal products on the market.
The objective of the Guidance Document is to provide guidance on how to interpret the outcome of individual tests and how to increase evidence on whether or not a substance may be an endocrine disrupter. However, testing strategies or guidance on interpretation from a suite of tests are not given.